South Korea, China lead degrader-antibody conjugate development: report | Asian Business Review
, APAC
184 views
Photo from Envato

South Korea, China lead degrader-antibody conjugate development: report

Companies from these countries collectively account for 19 out of 28 assets worldwide.

South Korea and China are leading in developing degrader-antibody conjugates (DACs), an emerging class of targeted therapy in precision medicine, said GlobalData.

DAC development is still in its early stages worldwide, with 28 assets in the pipeline. Of these, South Korean and Chinese companies collectively account for 19 assets.

“With these innovative assets, South Korean and Chinese companies can attract and expand their strategic collaborations with foreign players,” said Nadim Anwer, Pharma Analyst at GlobalData.

DACs are designed to overcome the limitations of traditional antibody-drug conjugates (ADCs) by combining the specificity of antibodies with the potency of protein degraders.

“It is too early to comment on the clinical success of this class; however, it is gaining attention as a new research area,” Anwer added.

Follow the link s for more news on

Dear Me Beauty berencana membuka flagship store

Store ini dapat menjadi fondasi bagi pertumbuhan pasar yang lebih luas.

Erajaya Digital membuka toko elektronik terbesarnya

Cabang ini merupakan toko konsep ke-80 dari sekitar seribu cabang yang tersebar di seluruh Indonesia.

Prudential, StanChart memperkuat 25 Tahun kemitraan bancassurance

Mereka memiliki kemitraan bancassurance terlama di Singapura dan Asia.

MSIG Asia dan RiskPoint mempertaruhkan asuransi energi terbarukan

Kawasan Asia-Pasifik berpotensi menarik investasi sebesar $3 triliun dalam pembangkitan listrik hingga 2033.

Industri kecantikan Jepang melawan produk palsu online dengan teknologi blockchain

Kemasan pintar membantu memastikan konsumen membeli produk asli.